Bristol-Myers Squibb Company· BMY
🇺🇸 US · LargeSP500NYSE
- Price
- $65.89
- Day
- +0.64%
- Mkt Cap
- $134.59B
- 52W Range
- $42.52 – $66.31
- Volume
- 17.29M
- Beta
- 0.23
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Amgen (AMGN). But which of these two stocks is more attractive to value investors?
Read full article
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Read full article
Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a Financial Times report over the weekend that the FTSE 100 drugmaker is in discussions over a merger with US rival Bristol Myers Squibb.
Read full article
Bristol Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read full article
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read full article
If maintained until close, the decline would be the stock's biggest one-day percentage fall since the day of the 2024 U.S. presidential election.
Read full article
AstraZeneca shares tumbled 7% in early trading on Monday following reports of talks between the European pharmaceutical giant and U.S.-based Bristol Myers Squibb , baffling investors and analysts.
Read full article
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled to explain why...
Read full article
Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britain's biggest drugmaker is in talks to buy its US rival,...
Read full article
Geopolitical relief triggered a sharp selloff in oil and a Treasury retreat, handing bulls an opening to reclaim momentum at the start of August, but a surprise move from MicroStrategy and a potential $400 billion pharma megadeal are reshaping the early narrative.
Read full article
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled to explain why Britain's largest drugmaker would want to buy Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). Jefferies described the reported talks as more than a 'head scratcher'.
Read full article